A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension

A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety and Efficacy of TAK-536, Amlodipine and Hydrochlorothiazide in Subjects With Essential Hypertension

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02277691

Enrollment

341

Registered

2014-10-29

Start date

2014-11-07

Completion date

2016-04-25

Last updated

2017-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Keywords

Pharmacological therapy, Drug Therapy

Brief summary

The purpose of this study is to evaluate the safety of long-term administration of TAK-536, amlodipine (AML), and hydrochlorothiazide (HCTZ) in participants with essential hypertension.

Detailed description

The drug being tested in this study is called TAK-536TCH. TAK-536TCH is being tested to treat people who have essential hypertension. The study looked at effectiveness and long-term safety of TAK-536TCH in people who took TAK-536CCB in addition to standard care. The study enrolled 341 patients. Participants received: * TAK-536CCB (as TAK-536/AML, 20 mg/5 mg) in run-in period, * TAK-536TCH (as TAK-536/ AML/HCTZ, 20 mg/5 mg/12.5 mg) in treatment period * TAK-536CCB and HCTZ 12.5 mg in treatment period All participants were asked to take tablets at the same time each day throughout the study. This multi-center trial was conducted in Japan. The overall time to participate in this study was 56 weeks (4 weeks run-in period and 52 weeks treatment period). Participants made multiple visits to the clinic during the study.

Interventions

DRUGTAK-536TCH tablet

TAK-536TCH tablets

DRUGTAK-536CCB tablet

TAK-536CCB tablets

DRUGHCTZ 12.5 mg tablet

HCTZ tablets

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

1. In the opinion of the investigator or subinvestigator, the participant is capable of understanding and complying with protocol requirements. 2. The participant signs and dates a written informed consent form prior to the initiation of any study procedures. 3. The participant has essential hypertension. 4. The participant has an office sitting systolic blood pressure (SBP) of \<180 mmHg and office sitting diastolic blood pressure (DBP) of \< 110 mmHg at the start of the run-in period (Week -4). Participants receiving combined therapy with a 3-drug antihypertensive within 4 weeks prior to the start of the run-in period is required to have an office sitting SBP of \< 160 mmHg and an office sitting DBP of \< 100 mmHg. 5. The participant's office sitting blood pressure at Week -2 and at the end of the run-in period (Week 0) need to be either: * Participants without concurrent diabetes mellitus or chronic kidney disease (CKD)\*: Sitting SBP of ≥ 140 mmHg or sitting DBP of ≥ 90 mmHg * Participants with concurrent diabetes mellitus or CKD\*: Sitting SBP of ≥ 130 mmHg or sitting DBP of ≥ 80 mmHg. * Estimate glomerular filtration rate according to creatinine (eGFRcreat) of \<60 mL/min/1.73 m\^2, or urinary albumin (spot urine) of ≥30 μg/mL in laboratory tests performed at Week -2 of the run-in period, and diagnosed with CKD by the investigator or subinvestigator. 6. The participant has an office sitting SBP of \< 160 mmHg and office sitting DBP of \< 100 mmHg at the end of the run-in period (Week 0). 7. The participant is male or female, aged 20 years or older at the time of providing informed consent. 8. The participant is an outpatient. 9. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agree to use routinely adequate contraception from signing of informed consent through 1 month following the end of the study.

Exclusion criteria

1. The participant has received any study drugs within 12 weeks prior to the start of the run-in period. 2. The participant has participated in another clinical study or a post-marketing study within 30 days prior to the start of the run-in period. 3. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g. spouse, parent, child, sibling), or may consent under duress. 4. The participant requires taking prohibited concomitant drugs during the study. 5. The participant has a history of hypersensitivity or allergies to TAK-536, AML, HCTZ, any thiazide diuretic or analog, any dihydropyridine drug, or any analog of TAK-536TCH. 6. The participant is judged by the investigator or subinvestigator to be in danger of experiencing an excessive increase in blood pressure when changing or discontinuing premedication. 7. The participant received combination therapy with antihypertensive drugs of the 3 ingredients contained in TAK-536TCH. 8. The participant received combined therapy with antihypertensive drugs, including 4 or more components, within 4 weeks prior to the start of the run-in period. 9. The participant has secondary or malignant hypertension. 10. The participant has a difference of ≥ 20 mmHg between left and right arms in office sitting SBP at the start of the run-in period (Week -4). 11. The participant has apparent white coat hypertension or exhibits a white coat effect. 12. . The participant has a day-night reversed lifestyle, such as those working during the night. 13. The participant has sleep apnea syndrome requiring treatment. 14. The participant has any of the following cardiovascular diseases: * Cardiac disease: Myocardial infarction\*, coronary arterial revascularization\*, severe valvular disorder, atrial fibrillation, any of the following conditions requiring treatment: angina pectoris, congestive heart failure, arrhythmia * Cerebrovascular disorders: Cerebral infarction/cerebral hemorrhage\*, transient ischemic attack\* * Vascular disease: Peripheral artery disease with intermittent claudication, artery dissection, aneurysm * Advanced hypertensive retinopathy: With bleeding or exudate/papilledema\*\* \* Occurring or performed within 24 weeks of the start of the run-in period \*\* Observed within 24 weeks of the start of the run-in period 15. The participant has a clinically apparent hepatic disorder (e.g., aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at Week -2 of the run-in period ≥ 2.5 times the upper limit of normal (ULN). 16. The participant has a clinically severe renal disorder (e.g., eGFRcreat in laboratory tests performed at Week -2 of run-in period \< 30 mL/minute/1.73 m\^2). 17. The participant's body fluid sodium or potassium level is markedly low\* or high\*. \*Based on normal ranges 18. The participant has gout or a history of gout within 24 weeks of the start of the run-in period or has hyperuricemia requiring drug treatment. 19. The participant has uncontrolled diabetes (e.g., HbA1c ≥ 7.4% in laboratory tests performed at Week -2 of the run-in period). 20. The participant has a malignant tumor. 21. If female, the participant is pregnant or lactating or before giving informed consent, intending to become pregnant or donate ova during or within 1 month after participating in the study. 22. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 2 years prior to the run-in period. 23. The participant who, in the opinion of the investigator or subinvestigator, is unsuitable for any other reason.

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants With Markedly Abnormal Vital Signs Values	Baseline up to Week 52	Vital signs included supine and standing systolic and diastolic blood pressure (SBP and DBP) respectively and office sitting pulse. Vital signs were considered abnormal if they were beyond the values defined in categories.
Number of Participants With Treatment Emergent Adverse Event (TEAE) Related to Electrocardiogram (ECG)	Baseline up to Week 52	Reported TEAE is categorized into cardiac disorders and investigations system organ class (SOC) related to ECG.
Number of Participants With Markedly Abnormal Clinical Laboratory Tests	Baseline up to Week 52	The number of participants with any markedly abnormal clinical laboratory test values collected throughout study. RBC = Red blood cells, ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyl transferase, LLN = lower limit of normal or lower reference limit, ULN = upper limit of normal or upper reference limit. Laboratory vallues were considered abnormal if they were beyond the values defined in categories.
Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Baseline up to Week 52	An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Number of Participants With Treatment Emergent Adverse Event (TEAE) Related to Body Weight	Baseline up to Week 52	Reported TEAE is categorized into investigations System Organ Class (SOC) related to body weight.

Secondary

Measure	Time frame	Description
Change From Baseline in Home Sitting Clinic Systolic and Diastolic Blood Pressure at Each Visit	Baseline (End of Run-in Period, Week 0), End of Week 12 and End of Treatment (Up to Week 52)	The change in home morning SPB and DBP measured at End of Week 12, End of Treatment (Up to Week 52) relative to baseline.
Change From Baseline in Office Trough Sitting Clinic Systolic and Diastolic Blood Pressure at Each Visit	Baseline (End of Run-in Period, Week 0) and Weeks 12 (LOCF) and 52 (LOCF)	The change in office trough SBP and DBP measured at Weeks 12 last observation was carried forward (LOCF) and 52 (LOCF) relative to baseline. Sitting blood pressure was measured at least 3 times. Each measurement session ended once blood pressure was found stable at 2 consecutive measurements. The average of the last 2 measurements of office sitting blood pressure was used.

Countries

Japan

Participant flow

Recruitment details

Participants took part in the study at 31 investigative sites in Japan, from 07 November 2014 to 25 April 2016.

Pre-assignment details

Participants with diagnosis of essential hypertension were enrolled in 1 treatment group:TAK-536CCB (TAK-536/ AML,20 mg/5 mg) in run-in period (Week -4 to 0).

Participants by arm

Arm	Count
TAK-536TCH For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/AML, 20 mg/5 mg, respectively) orally, once daily, before or after breakfast. For 48 weeks during 52 weeks of the treatment period, one tablet of TAK-536TCH (as TAK-536/AML/HCTZ, 20 mg/5 mg/12.5 mg, respectively) orally, once daily, before or after breakfast. For the remaining 4 weeks of the treatment period, one tablet each of TAK-536CCB and HCTZ 12.5 mg, orally, once daily, before or after breakfast.	341
Total	341

Arm

Count

TAK-536TCH

For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/AML, 20 mg/5 mg, respectively) orally, once daily, before or after breakfast. For 48 weeks during 52 weeks of the treatment period, one tablet of TAK-536TCH (as TAK-536/AML/HCTZ, 20 mg/5 mg/12.5 mg, respectively) orally, once daily, before or after breakfast. For the remaining 4 weeks of the treatment period, one tablet each of TAK-536CCB and HCTZ 12.5 mg, orally, once daily, before or after breakfast.

341

Total

341

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Lack of Efficacy	5
Overall Study	Pretreatment Event/Adverse Event	33
Overall Study	Used Other Antihypertensive Drug	1
Overall Study	Voluntary Withdrawal	7

Baseline characteristics

Characteristic	TAK-536TCH
Age, Continuous	60.8 years STANDARD_DEVIATION 11.44
BMI	26.20 kg/m^2 STANDARD_DEVIATION 3.883
Concurrent Chronic Kidney Disease	65 Participants
Concurrent Diabetes Mellitus	90 Participants
Concurrent Medical Conditions Cardiac Disease	11 Participants
Concurrent Medical Conditions Cerebrovascular Disorder	2 Participants
Concurrent Medical Conditions Dyslipidemia	174 Participants
Concurrent Medical Conditions Hepatic Disorder	43 Participants
Concurrent Medical Conditions Other Concurrent Medical Conditions	292 Participants
Concurrent Medical Conditions Vascular Disorder	21 Participants
Duration of Hypertension	9.42 years STANDARD_DEVIATION 7.728
Estimated Glomerular Filtration Rate According To Creatinine (eGFRcreat)	78.1 mL/min/1.73 m^2 STANDARD_DEVIATION 16.73
Height	164.1 cm STANDARD_DEVIATION 8.51
History of Alcohol Consumption	120 Participants
Medical History Cardiac Disease	9 Participants
Medical History Cerebrovascular Disorder	13 Participants
Medical History Dyslipidemia	1 Participants
Medical History Hepatic Disorder	2 Participants
Medical History Other Medical History	52 Participants
Medical History Vascular Disorder	1 Participants
Medication History (Antihypertensives) ACE Inhibitors	9 Participants
Medication History (Antihypertensives) ARBs	310 Participants
Medication History (Antihypertensives) CCBs	313 Participants
Medication History (Antihypertensives) Diuretics	66 Participants
Medication History (Antihypertensives) Other Antihypertensives	14 Participants
Medication History (Antihypertensives) β-blockers	19 Participants
Office Sitting Diastolic Blood Pressure (DBP)	86.2 mmHg STANDARD_DEVIATION 9.28
Office Sitting Systolic Blood Pressure (SBP)	143.7 mmHg STANDARD_DEVIATION 8.23
Region of Enrollment Japan	341 Participants
Sex: Female, Male Female	97 Participants
Sex: Female, Male Male	244 Participants
Smoking Classification Current Smoker	84 Participants
Smoking Classification Ex-Smoker	141 Participants
Smoking Classification Never Smoked	116 Participants
Weight	70.80 kg STANDARD_DEVIATION 12.943

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	195 / 341
serious Total, serious adverse events	20 / 341

Outcome results

Primary

Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame: Baseline up to Week 52